BLAINJECTIONINJECTABLE
Approved
Feb 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
SILIQ (brodalumab) by Bausch + Lomb is interleukin 17 receptor a antagonists [moa]. First approved in 2017.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SILIQ (brodalumab) is a monoclonal antibody that blocks interleukin-17 receptor A, a key driver of inflammatory pathways. It is approved for moderate-to-severe plaque psoriasis in adult patients. The drug represents a precision approach to immune-mediated skin disease by targeting a specific cytokine receptor.
$10MPart D
PeakPeak lifecycle stage with modest Part D volume suggests a mature, stable brand team focused on market maintenance rather than rapid expansion.
Mechanism of Action
Interleukin 17 Receptor A Antagonists
Pharmacologic Class:
Interleukin-17 Receptor A Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Brodalumab in the Treatment of Immune-Related Adverse Events
Started Mar 2025
11 enrolled
Breast CancerEsophageal CancerKidney Cancer+15 more
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
Started Dec 2022
12 enrolled
Psoriasis
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
Started Jul 2022
385 enrolled
Psoriasis Vulgaris
Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity
Started Oct 2021
394 enrolled
Psoriasis
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
Started Dec 2020
113 enrolled
Plaque PsoriasisPsoriasis VulgarisPsoriasis
Worked on SILIQ at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.